Clinical Trial Details

< Previous Trial     Next Trial >
Study ID NIDA-09260-3
Investigator
Walter Ling, M.D.,   Friends Research Institute, Inc.
Title Feasibility Study of Take-Home LAAM Medication - 3
Conditions Opioid-Related Disorders
Interventions Drug: LAAM
Phase Phase 4
Purpose The purpose of this study is to test therapeutic benefits of take-home LAAM. (1) Do subjects with take-home LAAM availability show increased clinical responsibility over subjects without; (2) Do subjects with take-home LAAM attempt diversion when random recall and other diversion safeguards are used; (3) Does treatment response correlate with background or drug use variables at intake, discharge, or during treatment?
Eligibility Ages Eligible: 18 Years
Genders Eligible:  Both
Accepts Healthy Volunteers:  No
Inclusion Criteria: meets DSM-IV criteria for opiate dependence. M/F, 18 years or older. Certified for LAAm treatment by a physician. Able to understand english. Willing to provide names, addresses, and numbers of 3 relatives who can aid in patient location for follow-up visits. Exclusion Criteria: Hypertensive to LAAM. Pregnant or nursing women. Female of childbearing potential who refuses to use an acceptable form of birth control. Clinically significant abnormality in hematology, blood work, or UA, ETOH and/or sedative/hypnotic dependence according to DSM-IV criteria. Medical or psychiatric illness which would jeopardize safe study participation.
Study Location
Friends Research Institute
Los Angeles, California, 90025
Contact N/A

Information objtained from ClinicalTrials.gov, on 4/18/2014. For additional information about this and other clinical trials, visit http://clinicaltrials.gov.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000300


Back to Search Results